SUPLEMENTARY FIGURE LEGENDS

Supplementary Figure S1. Acute responses of *Per1* promoter to treatment with several compounds. WT MEFs were transfected with Per1-dsluc and treated with ethanol (0.1%; sky line), DEX (1 μM; black line), DMSO (0.1%; gray line), forskolin (10 μM; green line), or ionomycin (1 μM; purple line) continuously during the real-time luminescence recording.

Supplementary Figure S2. Circadian oscillation patterns of *Per2* promoter serial deletion mutants. WT MEFs were transfected with *Per2* promoter serial deletion mutants: Per2 (-1671)::dsluc, Per2 (-271)::dsluc, Per2 (-201)::dsluc, or Per2 (-171)::dsluc. After 2-hr DEX (1 μM) treatment, *Per2* promoter activities were recorded by the real-time luminescence monitoring.

Supplementary Figure S3. DEX responsiveness of Per1 did not depend on E-box. (A) Schematic diagram of *Per1* promoter constructs. (B) WT or mutant constructs (GRE or E-box mutant) of the *Per1* promoter were transfected into WT MEFs. Cells were harvested after treatment with ethanol (0.1%) or DEX (1 μM) for 10-hr. Luciferase activities were normalized to renilla luciferase activities, and the fold induction was calculated as the ratio of the value of the DEX-treated group versus that of the ethanol-treated group. Values are the mean ± standard error of the mean (SEM) of three or four independent experiments performed in triplicates (*, $P < 0.05$).

Supplementary Figure S4. GBS responded to DEX in the absence of BMAL1. (A) The intron region containing GBS was subcloned into an SV40 promoter driven-luciferase (GBS-SV40P). (B) This construct was transfected into WT and *Bmal1*$^{-/-}$ MEFs, and cells were harvested after treatment with ethanol (0.1%) or DEX (1 μM) for 10-hr. Luciferase activities were normalized to renilla luciferase activities, and the fold induction was calculated as the ratio of the value of the DEX-treated group versus that of the ethanol-treated group. Values are the mean ± standard error of the mean (SEM) of three or four independent experiments performed in triplicates.

Supplementary Figure S5. Decreased GR levels in *Bmal1*$^{-/-}$ MEFs. WT and *Bmal1*$^{-/-}$ MEFs were harvested after treatment with ethanol (V; 0.1%) or DEX (D; 1 μM) for 1-hr. Western blot analysis was performed using GR, BMAL1, and tubulin antibodies.

Supplementary Figure S6. Circadian oscillation patterns of *Per2* induction mutant reporters. (A) WT or *Per2* induction mutant reporters (GRE^{mut} or E2^{mut}) were transfected into WT MEFs. Cells were treated with DEX (1 μM) for 2-hr, and bioluminescence was recorded by the real-time luminescence monitoring. (B) The phase of the second peak was measured for WT and *Per2* induction mutant reporters. Values are the mean ± standard error of the mean (SEM) of three or four independent experiments performed in triplicates.

Supplementary Figure S1.



Supplementary Figure S2.



Supplementary Figure S3.



Supplementary Figure S4.

A



B



Supplementary Figure S5.



Supplementary Figure S6.